Literature DB >> 14749340

Contribution of integrons, and SmeABC and SmeDEF efflux pumps to multidrug resistance in clinical isolates of Stenotrophomonas maltophilia.

Lin-Li Chang1, Hui-Feng Chen, Chung-Yu Chang, Tsong-Ming Lee, Wen-Jeng Wu.   

Abstract

OBJECTIVES: The contribution of integrons and efflux pumps to multidrug resistance in Stenotrophomonas maltophilia was evaluated.
MATERIALS AND METHODS: Ninety-three S. maltophilia clinical isolates were studied. PCR and direct sequencing were used to detect the presence of integrons. Real-time PCR was performed to assess and quantify the expression of the Sme efflux pumps of S. maltophilia.
RESULTS: Class 1 integrons were detected in 22% of clinical isolates and carried cassettes conferring resistance mainly to aminoglycosides and trimethoprim. The small multidrug resistance gene, smr, was found on class 1 integrons in six isolates. Thirty-one percent of the isolates overexpressed the smeDEF gene, as compared with a control strain, and 59% overexpressed the smeABC gene. Extrusion of ciprofloxacin and meropenem was specific to the SmeABC and SmeDEF pumps, respectively.
CONCLUSION: SmeABC and SmeDEF efflux pumps play important roles in resistance of S. maltophilia to ciprofloxacin and meropenem.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14749340     DOI: 10.1093/jac/dkh094

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  27 in total

Review 1.  Efflux-mediated drug resistance in bacteria: an update.

Authors:  Xian-Zhi Li; Hiroshi Nikaido
Journal:  Drugs       Date:  2009-08-20       Impact factor: 9.546

Review 2.  Xenobiotic efflux in bacteria and fungi: a genomics update.

Authors:  Ravi D Barabote; Jose Thekkiniath; Richard E Strauss; Govindsamy Vediyappan; Joe A Fralick; Michael J San Francisco
Journal:  Adv Enzymol Relat Areas Mol Biol       Date:  2011

Review 3.  The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.

Authors:  Xian-Zhi Li; Patrick Plésiat; Hiroshi Nikaido
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

4.  Identification of a novel 6'-N-aminoglycoside acetyltransferase, AAC(6')-Iak, from a multidrug-resistant clinical isolate of Stenotrophomonas maltophilia.

Authors:  Tatsuya Tada; Tohru Miyoshi-Akiyama; Rajan K Dahal; Shyam K Mishra; Kayo Shimada; Hiroshi Ohara; Teruo Kirikae; Bharat M Pokhrel
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

Review 5.  Stenotrophomonas maltophilia: an emerging global opportunistic pathogen.

Authors:  Joanna S Brooke
Journal:  Clin Microbiol Rev       Date:  2012-01       Impact factor: 26.132

Review 6.  Antimicrobial therapy for Stenotrophomonas maltophilia infections.

Authors:  A C Nicodemo; J I Garcia Paez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-04       Impact factor: 3.267

7.  The efflux pump SmeDEF contributes to trimethoprim-sulfamethoxazole resistance in Stenotrophomonas maltophilia.

Authors:  María Blanca Sánchez; José Luis Martínez
Journal:  Antimicrob Agents Chemother       Date:  2015-04-27       Impact factor: 5.191

8.  A specific polymerase chain reaction method to identify Stenotrophomonas maltophilia.

Authors:  Stephanie Wagner Gallo; Patrícia Locosque Ramos; Carlos Alexandre Sanchez Ferreira; Sílvia Dias de Oliveira
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-05       Impact factor: 2.743

9.  Overexpression of the Efflux Pumps SmeVWX and SmeDEF Is a Major Cause of Resistance to Co-trimoxazole in Stenotrophomonas maltophilia.

Authors:  María Blanca Sánchez; José Luis Martínez
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

Review 10.  Achromobacter xylosoxidans and Stenotrophomonas maltophilia: Emerging Pathogens Well-Armed for Life in the Cystic Fibrosis Patients' Lung.

Authors:  Quentin Menetrey; Pauline Sorlin; Estelle Jumas-Bilak; Raphaël Chiron; Chloé Dupont; Hélène Marchandin
Journal:  Genes (Basel)       Date:  2021-04-21       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.